Clinical trial
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the…
NCT00484536 · UCB Pharma, Industry · Terminated
Key facts
| NCT number | NCT00484536 |
|---|---|
| Title | Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323 |
| Official title | Double-blind, Placebo-controlled, Randomized, Parallel-group Phase II Study in Subjects With Relapsing Forms of Multiple Sclerosis (MS) to Evaluate the Safety, Tolerability, and Effects of CDP323. |
| Lead sponsor | UCB Pharma, Industry |
| Collaborators | Biogen Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | CDP323, placebo |
| Enrollment | 232 |
| Start date | May 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Jul 1, 2010 |
| First posted | Jun 11, 2007 |
| Last update posted | Sep 12, 2011 |
| Countries | Belgium, Canada, Finland, France, Germany, Hungary, Netherlands, Spain, Sweden, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: